FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765772292> ?p ?o ?g. }

• W2765772292 abstract "The newer 5-ASA preparations were intended to avoid the adverse effects of SASP while maintaining its therapeutic benefits. The efficacy and safety of 5-ASA preparations have been evaluated in numerous clinical trials that have often lacked sufficient statistical power to arrive at definitive conclusions. Previously, it was found that newer 5-ASA drugs were more effective than placebo but no more effective than SASP in inducing remission in ulcerative colitis. This updated review includes more recent studies and evaluates the effectiveness, dose-responsiveness, and safety of 5-ASA preparations in terms of more precise outcome measures.To assess the efficacy, dose-responsiveness and safety of the newer release formulations of 5-aminosalicylic acid (5-ASA) compared to placebo or sulfasalazine (SASP) in the maintenance of remission in ulcerative colitis.A computer-assisted literature search for relevant studies (1981-2002) was performed using MEDLINE, BIOS, the Cochrane Controlled Trials Register, the Cochrane IBD Group Specialized Trials Register, and the Science Citation Index, followed by a manual search of reference lists from previously retrieved articles, review articles, symposia proceedings, and abstracts from major gastrointestinal conferences.Studies were accepted for analysis if they were prospective, randomized, double-blinded, and placebo- or SASP-controlled clinical trials of parallel design with treatment duration of at least six months.Based on an intention to treat principle, the primary outcome was the failure to maintain clinical or endoscopic remission. Secondary outcomes were the number of patients experiencing adverse events, the number of patients withdrawn due to adverse events, and exclusions or withdrawals after entry into the study (not due to relapse). All data were analyzed using the Peto odds ratio and corresponding 95% confidence intervals (CI).The Peto odds ratio for the failure to maintain clinical or endoscopic remission (withdrawals and relapses) for 5-ASA versus placebo was 0.47 (95% CI, 0.36 to 0.62) with an NNT of 6. These values were also calculated for the trials in which SASP and 5-ASA were compared, revealing an odds ratio of 1.29 (95% CI, 1.05 to 1.57), with a negative NNT value (-19), suggesting a higher degree of therapeutic effectiveness for SASP. SASP and 5-ASA had similar adverse event profiles, with odds ratios of 1.16(0.62 to 2.16), and 1.31(0.86 to 1.99), respectively. The NNH values were determined to be 171 and 78 respectively.The newer 5-ASA preparations were superior to placebo in maintenance therapy. However, the newer preparations had a statistically significant therapeutic inferiority relative to SASP. This review updates the existing review of oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis which was published in the Cochrane Library (Issue 3, 2002)." @default.
• W2765772292 created "2017-11-10" @default.
• W2765772292 creator A5006407135 @default.
• W2765772292 creator A5057621778 @default.
• W2765772292 creator A5063956401 @default.
• W2765772292 creator A5084150670 @default.
• W2765772292 creator A5085660117 @default.
• W2765772292 date "2002-10-21" @default.
• W2765772292 modified "2023-10-17" @default.
• W2765772292 title "Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis" @default.
• W2765772292 cites W1497617769 @default.
• W2765772292 cites W1713443992 @default.
• W2765772292 cites W1968924987 @default.
• W2765772292 cites W1971737706 @default.
• W2765772292 cites W1973960461 @default.
• W2765772292 cites W1979915837 @default.
• W2765772292 cites W1981227935 @default.
• W2765772292 cites W1981655586 @default.
• W2765772292 cites W1984725180 @default.
• W2765772292 cites W1988770901 @default.
• W2765772292 cites W1991187575 @default.
• W2765772292 cites W1994808035 @default.
• W2765772292 cites W1995574368 @default.
• W2765772292 cites W1996166904 @default.
• W2765772292 cites W1998652812 @default.
• W2765772292 cites W2000620826 @default.
• W2765772292 cites W2000841211 @default.
• W2765772292 cites W2002136844 @default.
• W2765772292 cites W2005382316 @default.
• W2765772292 cites W2008750336 @default.
• W2765772292 cites W2027122987 @default.
• W2765772292 cites W2028851330 @default.
• W2765772292 cites W2043258441 @default.
• W2765772292 cites W2044507601 @default.
• W2765772292 cites W2045636889 @default.
• W2765772292 cites W2051101606 @default.
• W2765772292 cites W2053331429 @default.
• W2765772292 cites W2055909907 @default.
• W2765772292 cites W2056817635 @default.
• W2765772292 cites W2057483013 @default.
• W2765772292 cites W2058746051 @default.
• W2765772292 cites W2065780155 @default.
• W2765772292 cites W2068503564 @default.
• W2765772292 cites W2069718379 @default.
• W2765772292 cites W2085758198 @default.
• W2765772292 cites W2090568923 @default.
• W2765772292 cites W2096326818 @default.
• W2765772292 cites W2098013182 @default.
• W2765772292 cites W2102818528 @default.
• W2765772292 cites W2113665422 @default.
• W2765772292 cites W2114959701 @default.
• W2765772292 cites W2124177455 @default.
• W2765772292 cites W2129196336 @default.
• W2765772292 cites W2135287750 @default.
• W2765772292 cites W2161667176 @default.
• W2765772292 cites W2171789845 @default.
• W2765772292 cites W2179681930 @default.
• W2765772292 cites W2411840308 @default.
• W2765772292 cites W2415775034 @default.
• W2765772292 cites W315764148 @default.
• W2765772292 cites W4233953501 @default.
• W2765772292 cites W4243357235 @default.
• W2765772292 doi "https://doi.org/10.1002/14651858.cd000544" @default.
• W2765772292 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12519547" @default.
• W2765772292 hasPublicationYear "2002" @default.
• W2765772292 type Work @default.
• W2765772292 sameAs 2765772292 @default.
• W2765772292 citedByCount "54" @default.
• W2765772292 countsByYear W27657722922012 @default.
• W2765772292 countsByYear W27657722922013 @default.
• W2765772292 countsByYear W27657722922014 @default.
• W2765772292 countsByYear W27657722922015 @default.
• W2765772292 countsByYear W27657722922016 @default.
• W2765772292 countsByYear W27657722922017 @default.
• W2765772292 countsByYear W27657722922019 @default.
• W2765772292 countsByYear W27657722922021 @default.
• W2765772292 countsByYear W27657722922022 @default.
• W2765772292 crossrefType "reference-entry" @default.
• W2765772292 hasAuthorship W2765772292A5006407135 @default.
• W2765772292 hasAuthorship W2765772292A5057621778 @default.
• W2765772292 hasAuthorship W2765772292A5063956401 @default.
• W2765772292 hasAuthorship W2765772292A5084150670 @default.
• W2765772292 hasAuthorship W2765772292A5085660117 @default.
• W2765772292 hasConcept C126322002 @default.
• W2765772292 hasConcept C142724271 @default.
• W2765772292 hasConcept C168563851 @default.
• W2765772292 hasConcept C17744445 @default.
• W2765772292 hasConcept C177713679 @default.
• W2765772292 hasConcept C197934379 @default.
• W2765772292 hasConcept C199539241 @default.
• W2765772292 hasConcept C204787440 @default.
• W2765772292 hasConcept C27081682 @default.
• W2765772292 hasConcept C2779134260 @default.
• W2765772292 hasConcept C2779383735 @default.
• W2765772292 hasConcept C2779473830 @default.
• W2765772292 hasConcept C2780479503 @default.
• W2765772292 hasConcept C535046627 @default.
• W2765772292 hasConcept C71924100 @default.
• W2765772292 hasConceptScore W2765772292C126322002 @default.
• W2765772292 hasConceptScore W2765772292C142724271 @default.

• next